Isoherranen N - Search Results

1

Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N. Lutz JD, et al. Among authors: isoherranen n. Drug Metab Dispos. 2013 Dec;41(12):2056-65. doi: 10.1124/dmd.113.052639. Epub 2013 Jun 19. Drug Metab Dispos. 2013. PMID: 23785064 Free PMC article.

2

Drugs Form Ternary Complexes with Human Liver Fatty Acid Binding Protein (FABP1) and FABP1 Binding Alters Drug Metabolism.

Yabut KCB, Martynova A, Nath A, Zercher BP, Bush MF, Isoherranen N. Yabut KCB, et al. Among authors: isoherranen n. bioRxiv [Preprint]. 2024 Jan 19:2024.01.17.576032. doi: 10.1101/2024.01.17.576032. bioRxiv. 2024. PMID: 38293009 Free PMC article. Updated. Preprint.

3

Role of itraconazole metabolites in CYP3A4 inhibition.

Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Isoherranen N, et al. Drug Metab Dispos. 2004 Oct;32(10):1121-31. doi: 10.1124/dmd.104.000315. Epub 2004 Jul 8. Drug Metab Dispos. 2004. PMID: 15242978

4

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Huang W, et al. Among authors: isoherranen n. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21. Drug Metab Dispos. 2004. PMID: 15383492

5

Stereochemical aspects of itraconazole metabolism in vitro and in vivo.

Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. Kunze KL, et al. Among authors: isoherranen n. Drug Metab Dispos. 2006 Apr;34(4):583-90. doi: 10.1124/dmd.105.008508. Epub 2006 Jan 13. Drug Metab Dispos. 2006. PMID: 16415110 Clinical Trial.

6

Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.

Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE. Dai Y, et al. Among authors: isoherranen n. Drug Metab Dispos. 2006 May;34(5):836-47. doi: 10.1124/dmd.105.008680. Epub 2006 Feb 24. Drug Metab Dispos. 2006. PMID: 16501005

7

Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.

Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM. Pearson JT, et al. Among authors: isoherranen n. Biochemistry. 2006 May 23;45(20):6341-53. doi: 10.1021/bi0600042. Biochemistry. 2006. PMID: 16700545 Free PMC article.

8

Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N. Templeton IE, et al. Among authors: isoherranen n. Clin Pharmacol Ther. 2008 Jan;83(1):77-85. doi: 10.1038/sj.clpt.6100230. Epub 2007 May 9. Clin Pharmacol Ther. 2008. PMID: 17495874 Free PMC article. Clinical Trial.

9

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.

Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. Isoherranen N, et al. Drug Metab Dispos. 2008 Jan;36(1):146-54. doi: 10.1124/dmd.107.018382. Epub 2007 Oct 22. Drug Metab Dispos. 2008. PMID: 17954524

10

Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. Lutz JD, et al. Among authors: isoherranen n. Biochem Pharmacol. 2009 Jan 15;77(2):258-68. doi: 10.1016/j.bcp.2008.10.012. Epub 2008 Oct 17. Biochem Pharmacol. 2009. PMID: 18992717 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page